Royalty Pharma plc - Class A

RPRX

$28.76

-36.4% last 12 months

Baillie Gifford Holding value: $525 Million Andreas Halvorsen Holding value: $272 Million Steven Cohen Holding value: $20.9 Million Jim Simons Holding value: $13.9 Million Paul Tudor Jones II Holding value: $6.01 Million Ray Dalio Holding value: $5.56 Million Ken Griffin Holding value: $3.54 Million Jefferies Group Holding value: $673 Thousand Warren Buffett Holding value: $0

Market Cap

$12 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$25.54 - $42.78

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

65.31x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.79 (2.91%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $12 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $17.2 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.79 (2.91%)
1 Year Return Profit or loss of share price change plus dividend yield. -33.5%
52-Week High Highest share price in the last 52 weeks. $42.78
52-Week Low Lowest share price in the last 52 weeks. $25.54
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.0
Outstanding Shares The number of shares the company has issued and are held by stockholders. 445 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 2.18 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 65.31
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -132.07
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $0.42
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 5.75
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 2.21
Enterprise Value to Revenue Enterprise value divided by revenue 7.41
Enterprise Value to EBIT Enterprise Value divided by EBIT 16.66
Total Debt to Enterprise Value Total debt divided by enterprise value 0.36
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 1.0

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $2.32 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $2.32 Billion
EBIT Earnings before tax and interest payments. $1.03 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $184 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 7.93%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -49.4%
Return on Equity Equity divided by market cap. 3.00%
Return on Assets Indicates a company's profitability in relation to its total assets. 1.16%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 6.58%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q1 2023 Q2 2023 Q3 2023 Q4 2023

Similar stocks

ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc
Abbott Laboratories
Abbott Laboratories
Lilly(Eli) & Co
Lilly(Eli) & Co
Sophiris Bio Inc
Sophiris Bio Inc

News

Portolan Capital Management LLC Cuts Stake in Royalty Pharma plc (NASDAQ:RPRX)

Portolan Capital Management LLC Cuts Stake in Royalty Pharma plc (NASDAQ:RPRX)

Portolan Capital Management LLC lowered its position in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 34.8% in the second quarter, according to...

The AM Reporter The AM Reporter, 2 days ago
Royalty Pharma ownership shows strong institutional and insider confidence

Royalty Pharma ownership shows strong institutional and insider confidence

https://www.investing.com/news/stock-market-news/royalty-pharma-ownership-shows-strong-institutional-and-insider-confidence-93CH-3243292

Investing.com Investing.com, 11 days ago
ExodusPoint Capital Management LP Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

ExodusPoint Capital Management LP Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

… ’s stock. Royalty Pharma Stock Performance Shares of … Research Report on Royalty Pharma Royalty Pharma Profile (Free Report) … cap biotechnology companies...

EIN News Pharmaceuticals EIN News Pharmaceuticals, 16 days ago
Teva signs $125m deal with Royalty Pharma on antipsychotic drug

Teva signs $125m deal with Royalty Pharma on antipsychotic drug

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to accelerate the clinica...

TheAdviserMagazine.com TheAdviserMagazine.com, 24 days ago
Never miss a trade
To improve your user experience we use cookies.